A	B	C
1	Main
2		Brand Name	Tabrecta, fka INCB28060
3		Indication	Solid tumors
4		Mechanism	c-MET inhibitor
5			V617F mutation is acquired in MF patients.
6		Administration	Oral
7		Economics	NVS
8		IP
9		Clinical Trials
10			Phase II "GEOMETRY mono-1"
11			52% ORR in 2L, 44% ITT
12
13			Phase 1, n = 40
14			Dose escalation.
15			Data expected Q1 2012
16			Per 10-k, compnay expects to transtion this drug to NVS once done.